JAKAVI®


Tablets
scheduling status
S4
registration number
48/34/0109, 52/34/0781, 48/34/0110, 48/34/0111
What JAKAVI® contains
JAKAVI® 5 mg tablets: Each tablet contains 5 mg ruxolitinib (as phosphate). JAKAVI® 10 mg tablets: Each tablet contains 10 mg ruxolitinib (as phosphate). JAKAVI® 15 mg tablets: Each tablet contains 15 mg ruxolitinib (as phosphate). JAKAVI® 20 mg tablets: Each tablet contains 20 mg ruxolitinib (as phosphate).
other ingredients
Cellulose, microcrystalline; magnesium stearate; silica, colloidal anhydrous; sodium starch glycolate (Type A); povidone K30; hydroxypropylcellulose 300 to 600 cps; lactose monohydrate.
Therapeutic classification
L01XE18 Antineoplastic agents, protein kinase inhibitors.
© 2026 SAHPRA. ALL RIGHTS RESERVED